Suivre
Simon Pacey
Simon Pacey
Department of Oncology, University of Cambridge
Adresse e-mail validée de medschl.cam.ac.uk - Page d'accueil
Titre
Citée par
Citée par
Année
Liquid biopsies come of age: towards implementation of circulating tumour DNA
JCM Wan, C Massie, J Garcia-Corbacho, F Mouliere, JD Brenton, ...
Nature Reviews Cancer 17 (4), 223-238, 2017
21632017
Enhanced detection of circulating tumor DNA by fragment size analysis
F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ...
Science translational medicine 10 (466), eaat4921, 2018
8082018
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji, A O'Donnell, M Scurr, S Pacey, S Stapleton, Y Asad, ...
Journal of Clinical Oncology 23 (18), 4152-4161, 2005
5682005
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
CS Tan, D Gilligan, S Pacey
The lancet oncology 16 (9), e447-e459, 2015
3872015
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
R Plummer, G Attard, S Pacey, L Li, A Razak, R Perrett, M Barrett, ...
Clinical cancer research 13 (20), 6187-6194, 2007
2962007
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
S Pacey, RH Wilson, M Walton, MM Eatock, A Hardcastle, A Zetterlund, ...
Clinical cancer research 17 (6), 1561-1570, 2011
2252011
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
S Pacey, M Gore, D Chao, U Banerji, J Larkin, S Sarker, K Owen, Y Asad, ...
Investigational new drugs 30, 341-349, 2012
1592012
Hsp90 inhibitors in the clinic
S Pacey, U Banerj, I Judson, P Workman
Molecular Chaperones in Health and Disease, 331-358, 2006
1362006
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with …
JS de Bono, R Kristeleit, A Tolcher, P Fong, S Pacey, V Karavasilis, ...
Clinical Cancer Research 14 (20), 6663-6673, 2008
1332008
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells
N Gaspar, SY Sharp, S Pacey, C Jones, M Walton, G Vassal, S Eccles, ...
Cancer research 69 (5), 1966-1975, 2009
1302009
Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers
E Beddowes, J Spicer, PY Chan, R Khadeir, JG Corbacho, D Repana, ...
Journal of Clinical Oncology 35 (16), 1778, 2017
1132017
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS–RAF mutations
L Zimmer, F Barlesi, M Martinez-Garcia, V Dieras, JHM Schellens, ...
Clinical Cancer Research 20 (16), 4251-4261, 2014
802014
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin
UN Vaishampayan, AM Burger, EA Sausville, LK Heilbrun, J Li, ...
Clinical Cancer Research 16 (14), 3795-3804, 2010
652010
A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma
PE Hall, R Lewis, N Syed, R Shaffer, J Evanson, S Ellis, M Williams, ...
Clinical Cancer Research 25 (9), 2708-2716, 2019
542019
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
S Pacey, MJ Ratain, KT Flaherty, SB Kaye, L Cupit, EK Rowinsky, C Xia, ...
Investigational new drugs 29, 481-488, 2011
512011
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced …
A Greystoke, S Blagden, AL Thomas, E Scott, G Attard, R Molife, L Vidal, ...
Annals of oncology 17 (8), 1313-1319, 2006
442006
Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
I Hudecova, CG Smith, R Hänsel-Hertsch, CS Chilamakuri, JA Morris, ...
Genome research 32 (2), 215-227, 2022
402022
A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo
LD Cassidy, ARJ Young, PA Pérez-Mancera, B Nimmervoll, A Jaulim, ...
Autophagy 14 (7), 1256-1266, 2018
402018
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development
D Sarker, S Pacey, P Workman
Future Medicine Ltd 1 (3), 399-417, 2007
322007
Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers
S Pacey, D Rea, N Steven, C Brock, N Knowlton, N Shand, K Hazell, ...
Journal of Clinical Oncology 22 (14_suppl), 3120-3120, 2004
302004
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20